A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Phase 2a Study to Investigate Efficacy and Safety of Zabedosertib (BAY 1834845) for the Treatment of Adult Patients With Moderate-to-severe Atopic Dermatitis
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Zabedosertib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms Damask
- Sponsors Bayer
Most Recent Events
- 26 Feb 2024 Status changed from active, no longer recruiting to completed.
- 24 Jan 2024 Planned End Date changed from 29 Jan 2024 to 31 Jan 2024.
- 29 Dec 2023 This trial has been completed in France as per European Clinical Trials Database record.